Market closed
Viatris/$VTRS
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Viatris
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
Ticker
$VTRS
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
32,000
Website
Viatris Metrics
BasicAdvanced
$16B
Market cap
-
P/E ratio
-$0.74
EPS
0.93
Beta
$0.48
Dividend rate
3.59%
Dividend yield
Price and volume
Market cap
$16B
Beta
0.93
52-week high
$13.62
52-week low
$9.08
Average daily volume
6.9M
Dividend rate
$0.48
Financial strength
Current ratio
1.505
Quick ratio
0.745
Long term debt to equity
72.267
Total debt to equity
79.577
Interest coverage (TTM)
3.24%
Management effectiveness
Return on assets (TTM)
2.47%
Return on equity (TTM)
-4.34%
Valuation
Price to revenue (TTM)
1.062
Price to book
0.81
Price to tangible book (TTM)
-2.06
Price to free cash flow (TTM)
8.384
Dividend yield (TTM)
3.59%
Forward dividend yield
3.59%
Growth
Revenue change (TTM)
-2.70%
Earnings per share change (TTM)
-148.82%
3-year revenue growth (CAGR)
-4.30%
3-year earnings per share growth (CAGR)
-24.47%
3-year dividend per share growth (CAGR)
13.30%
What the Analysts think about Viatris
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Viatris stock.
Viatris Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Viatris Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Viatris News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Market closed
Upcoming events
Dec
13
Viatris
Dividend·Payment
$0.12
Per share
FAQs
What’s the current market cap for Viatris stock?
Viatris (VTRS) has a market cap of $16B as of November 24, 2024.
What is the P/E ratio for Viatris stock?
The price to earnings (P/E) ratio for Viatris (VTRS) stock is 0 as of November 24, 2024.
Does Viatris stock pay dividends?
Yes, the Viatris (VTRS) stock pays dividends to shareholders. As of November 24, 2024, the dividend rate is $0.48 and the yield is 3.59%. Viatris has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Viatris dividend payment date?
The next Viatris (VTRS) dividend payment is scheduled for December 13, 2024.
What is the beta indicator for Viatris?
Viatris (VTRS) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.